VarmX bags €32m in Series B roundLeiden-based coagulant developer VarmX NV has closed a €32m Series B financing to push clinical development of VMX-C001, a venom-based modified recombinant Factor X. more ➔
APEIRON Biologics licences MaxCytes elec...Viennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcytes electroporation platform for APN401 development. more ➔
Immatics launches US$250m Nasdaq-IPOAfter closing the business merging with blank check company Arya Sciences Acquisition Corp, Immatics Inc has been listed on Nasdaq. more ➔
New insulin formulation allows faster bloo...A new insulin formulation allows patients with diabetes to more quickly manage their blood sugar levels during mealtimes. more ➔
COVID-19: Lopinavir-ritonavir failedData from the UKs RECOVERY trial demonstrate there was no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients. more ➔
EC pledges €4.9bn to grant access to med...Under the Coronavirus Global Response Framework, the European Commission is allocating further €4.9bn to assure access to COVID-19 countermeasures for poor countries. more ➔
BioGeneration Ventures closes BGV IV Fund...BioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at €105m. more ➔
LSP leads €11m Series A round in OneProj...OneProjects Ltd, an Irish-German cardiac imaging specialist, has closed an €11m Series A financing led by Amsterdam-headquartered life sciences investor LSP. more ➔
Illumina and Epidarex Capital invest in po...Illumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs. more ➔
Novel adjuvant teases T cells to respond t... Researchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response. more ➔
